Table 1 Patient baseline characteristics (n = 93)
Characteristic | Rituximab (n = 26) | Natalizumab (n = 50) | Ocrelizumab (n = 17) | Frequency (%) |
|---|---|---|---|---|
Gender, (n, %) | Â | Â | Â | Â |
Male | 12(46.2) | 16(32.0) | 8(47.1) | 36(38.7) |
Female | 14(53.9) | 34(68.0) | 9(52.9) | 57(61.3) |
Age, (n, %) | Â | Â | Â | Â |
16 yrs.—25 yrs. | 15(57.7) | 11(22.0) | 1(5.9) | 27(29.0) |
26 yrs.—35 yrs. | 7(26.9) | 25(50.0) | 12(70.6) | 44(47.3) |
36 yrs. —45 yrs. | 3(11.5) | 10(20.0) | 2(11.8) | 15(16.1) |
> 45 yrs. | 1(3.9) | 4(8.0) | 2(11.8) | 7(7.5) |
Duration of illness, (n, %) | Â | Â | Â | Â |
≤ 2 yrs. | 13(50.0) | 6(12.0) | 0(0.0) | 19(20.4) |
2 yrs. – ≤4 yrs. | 9(34.6) | 8(16.0) | 1(5.9) | 18(19.4) |
4 yrs. – ≤8 yrs. | 4(15.4) | 31(62.0) | 11(64.7) | 46(49.5) |
> 8 yrs. | 0(0.0) | 5(10.0) | 5(29.4) | 10(10.8) |
Duration of therapy, (n, %) | Â | Â | Â | Â |
6 months − 1 year. | 5(19.2) | 9(18.0) | 16(94.1) | 15(16.1) |
1 year. – 2 yrs. | 12(46.2) | 14(28.0) | 1(5.9) | 42(45.2) |
2 yrs. – 3 yrs. | 5(19.2) | 14(28.0) | 0(0.0) | 19(20.4) |
> 3 yrs. | 4(15.4) | 13(26.0) | 0(0.0) | 17(18.3) |
Number of used DMTs, (n, %) | Â | Â | Â | Â |
1 | 7(26.9) | 49(98.0) | 2(11.8) | 58(62.4) |
2 | 14(53.9) | 1(2.0) | 8(47.1) | 23(24.7) |
> 2 | 5(19.2) | 0(0.0) | 7(41.2) | 12(12.9) |
Other comorbid health conditions (e.g., hypertension, diabetes, dyslipidemia), (n, %) | Â | Â | Â | Â |
No | 2(7.7) | 42(16.0) | 6(35.3) | 16(17.2) |
Yes | 2(7.7) | 8(16.0) | 6(35.3) | 16(17.2) |